Mutational Status of Codons 12 and 13 of the N- andK-rasGenes in Tissue and Cell Lines Derived from Primary and Metastatic Prostate Carcinomas
- 1 January 1993
- journal article
- research article
- Published by Taylor & Francis in Cancer Investigation
- Vol. 11 (1), 25-32
- https://doi.org/10.3109/07357909309020257
Abstract
N- and K-ras mutations at codons 12 and 13 were investigated using oligonucleotide hybridization analysis after PCR amplification and subsequent sequence analysis of the amplfied DNA from the region of interest in the following prostatic primary and metastatic (met) carcinoma-derived cell lines: 1013L (primary), PC3 (bone met), DU145 (brain met), und LNCaP (lymph node met). We also examined fresh and archival primary and metastatic prostate tumor tissue and benign prostatic hypertrophy specimens. All prostatic cells and tissues examined contain at least one wild-type N- and K-ras allele with respect to codons 12 and 13. No mutations were found at N-ras codon 13. The only mutation seen in the prostatic cell lines and tissues was a K-ras codon 12 position II G-to-T transversion. Since these are established nonclonal cell lines that have adapted to tissue culture, it is possible that this mutation does not represent the mutational state of prostatic curcinoma in vivo. However, the lack of consistent mutation in the ras genes amplified directly from tumors suggests that when ras mutations occur during the progression of prostatic carcinoma, they are Late-stage events not directly involved in the initial development of disease. lmmunoprecipitation studies using pan-ras antibodies revealed no evidence of altered expression of Ras proteins.Keywords
This publication has 4 references indexed in Scilit:
- POINT MUTATION IN c-HA-ras ONCOGENE IN NORMAL AND ABNORMAL CELLSThe Lancet, 1989
- The ras gene family and human carcinogenesisMutation Research/Reviews in Genetic Toxicology, 1988
- Activated ki‐ras oncogene in human prostatic adenocarcinomaThe Prostate, 1987
- Expression ofrasOncogene p21 in Prostate CancerNew England Journal of Medicine, 1986